Avior Wealth Management LLC Raises Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Avior Wealth Management LLC grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 21.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 6,456 shares of the company’s stock after buying an additional 1,124 shares during the quarter. Avior Wealth Management LLC’s holdings in Vaxcyte were worth $528,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Vaxcyte by 68.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock valued at $2,453,000 after purchasing an additional 8,685 shares during the last quarter. Natixis Advisors LLC increased its holdings in Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after buying an additional 8,606 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Vaxcyte in the second quarter valued at $1,053,000. Lisanti Capital Growth LLC lifted its holdings in Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after buying an additional 13,175 shares during the last quarter. Finally, Diversified Trust Co purchased a new position in shares of Vaxcyte in the 4th quarter valued at about $1,433,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Down 0.4 %

Vaxcyte stock opened at $89.64 on Friday. The stock has a market capitalization of $11.17 billion, a price-to-earnings ratio of -19.49 and a beta of 0.98. The stock has a 50 day moving average of $87.29 and a two-hundred day moving average of $93.92. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the business earned ($0.91) earnings per share. Equities analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Activity

In other news, SVP Mikhail Eydelman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total value of $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares of the company’s stock, valued at $2,625,488.53. This trade represents a 14.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00. Following the transaction, the chief executive officer now directly owns 435,219 shares in the company, valued at $46,490,093.58. This represents a 3.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,982 shares of company stock valued at $8,108,425 over the last quarter. Corporate insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.